WALTHAM, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) — Eloxx Prescribed drugs, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical firm devoted to the invention and growth of novel therapeutics to deal with cystic fibrosis and different illnesses brought on by nonsense mutations limiting manufacturing of practical proteins, as we speak introduced that it’ll launch its third quarter 2020 monetary and operational outcomes and host a convention name and stay webcast on Thursday, November 5, 2020.
Convention Name Info:
Date: Thursday, November 5, 2020
Time: 4:30 p.m. ET
Home Dial-in Quantity: (866) 913-8546
Worldwide Dial-in Quantity: (210) 874-7715
Convention ID: 9467336
About Eloxx Prescribed drugs
Eloxx Prescribed drugs, Inc. is a clinical-stage biopharmaceutical firm growing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) which might be formulated to deal with uncommon and ultra-rare untimely cease codon illnesses. Untimely cease codons are level mutations that disrupt protein synthesis from messenger RNA. As a consequence, sufferers with untimely cease codon illnesses have lowered or eradicated protein manufacturing from the mutation bearing allele accounting for among the most extreme phenotypes in these genetic illnesses. These untimely cease codons have been recognized in over 1,800 uncommon and ultra-rare illnesses. Learn-through therapeutic growth is concentrated on extending mRNA half-life and growing protein synthesis by enabling the cytoplasmic ribosome to learn by means of untimely cease codons to provide full-length proteins. Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to revive manufacturing of full-length practical proteins. ELX-02 is within the early phases of scientific growth specializing in cystic fibrosis. ELX-02 is an investigational drug that has not been authorised by any world regulatory physique. Eloxx’s preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides recognized primarily based on read-through potential. Eloxx additionally has preclinical applications centered on kidney illnesses together with autosomal dominant polycystic kidney illness, in addition to uncommon ocular genetic issues. Eloxx is headquartered in Waltham, MA, with operations in Rehovot, Israel and Morristown, NJ. For extra data, please go to www.eloxxpharma.com.
This press launch incorporates forward-looking statements, that are usually statements that aren’t historic information. Ahead-looking statements may be recognized by the phrases “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and comparable expressions. Ahead-looking statements are primarily based on administration’s present plans, estimates, assumptions and projections, and converse solely as of the date they’re made. We undertake no obligation to replace any forward-looking assertion in gentle of recent data or future occasions, besides as in any other case required by regulation. Ahead-looking statements contain inherent dangers and uncertainties, most of that are troublesome to foretell and are usually past our management. Precise outcomes or outcomes could differ materially from these implied by the forward-looking statements because of the affect of quite a few elements, together with: the event of the Firm’s read-through know-how; the approval of the Firm’s patent functions; the Firm’s skill to efficiently defend its mental property or acquire essential licenses at a value acceptable to the Firm, if in any respect; the profitable implementation of the Firm’s analysis and growth applications and collaborations; the Firm’s skill to acquire relevant regulatory approvals for its present and future product candidates; the acceptance by the market of the Firm’s merchandise ought to they obtain regulatory approval; the timing and success of the Firm’s preliminary research, preclinical analysis, scientific trials, and associated regulatory filings; the flexibility of the Firm to consummate further financings as wanted; the affect of worldwide well being considerations, such because the COVID-19 world pandemic, on our skill to proceed our scientific and preclinical applications and in any other case function our enterprise successfully; in addition to these mentioned in additional element in our Annual Report on Kind 10-Okay and our different reviews filed with the Securities and Change Fee.
SOURCE: Eloxx Prescribed drugs, Inc.